Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 3/20 | 0.42 |
| ▸ | CTSD | P07339 | 2/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30563216 | 0.96 | DPP4 (0.48) | DPP4DPP8DPP9OPRD1OPRM1 | |
| SCHEMBL30555686 | 0.91 | DPP4 (0.45) | DPP4DPP8DPP9OPRD1OPRM1 | |
| SCHEMBL30662554 | 0.91 | OPRD1 (0.43) | OPRD1OPRM1OPRK1GLO1PTGS1 | |
| SCHEMBL29670065 | 0.90 | PTGS1 (0.48) | DPP4DPP8DPP9GLO1PTGS1 | |
| SCHEMBL30563222 | 0.89 | OPRD1 (0.44) | DPP4DPP8DPP9OPRD1OPRM1 | |
| SCHEMBL6049343 | 0.88 | BACE1 (0.48) | GLO1BACE1CTSD | |
| SCHEMBL6049342 | 0.88 | BACE1 (0.48) | GLO1BACE1CTSD | |
| SCHEMBL30563224 | 0.88 | OPRD1 (0.48) | DPP4DPP8DPP9OPRD1OPRM1 | |
| SCHEMBL29630511 | 0.88 | OPRD1 (0.45) | DPP4DPP8DPP9OPRD1OPRM1 | |
| SCHEMBL34464998 | 0.87 | DPP4 (0.51) | DPP4DPP8DPP9NOD1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12257323-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11865192-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3436012-B1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES INC (US) | 2023-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | MMP8, CD68, ELANE | DPP4 462/4885DPP8 398/4885DPP9 281/4885 |
| US-11865192-B2 | Modified wound dressings | MMP8, CD68, ELANE | DPP4 462/4885DPP8 398/4885DPP9 281/4885 |
| US-12257323-B2 | Modified wound dressings | MMP8, CD68, ELANE | DPP4 462/4885DPP8 398/4885DPP9 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.